Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Management tracks: AbbVie, Semma, Ziopharm

December 18, 2018 11:20 PM UTC

AbbVie Inc. (NYSE:ABBV) unveiled a new executive leadership team. It includes EVP of R&D and CSO Michael Severino, who will become vice chairman and president and be responsible for R&D, HR, operations and the corporate strategy office; EVP of External Affairs and General Counsel Laura Schumacher, who will become vice chairman of external affairs and chief legal officer; EVP of Commercial Operations Carlos Alban, who will become vice chairman and chief commercial officer; and William Chase, who remains EVP of finance and administration. All four executives report to Chairman and CEO Richard A. Gonzalez.

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) hired David Lebwohl as CMO and David DiGiusto as CTO. Lebwohl was SVP and franchise global program head of the CAR T team at Novartis AG (NYSE:NVS; SIX:NOVN) and DiGiusto was executive director of stem cell and cellular therapeutics operations at Stanford University (Stanford, Calif.). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article